Download PDF

ES Journal of Oncology

DOI: 10.59152/ESJO/1005

Molecular Histopathology of Benign Uterine Mesenchymal Tumors.

  • Editorial

  • Takuma Hayashi1*; Nobuo Yaegashi2; Susumu Tonegawa3 and Ikuo Konishi1,4
  • 1Department of Cancer Medicine, National Hospital Organization Kyoto Medical Center, Japan.
  • 2Department of Obstetrics and gynecology, Tohoku University School of Medicine, Japan.
  • 3Department of Biology, Massachusetts Institute of Technology, USA.
  • 4Department of Obstetrics and gynecology, Kyoto University School of Medicine, Japan.
  • *Corresponding author: Takuma Hayashi, Department of Cancer Medicine, National Hospital Organization Kyoto Medical Center, Japan.
  • Received: Feb 07, 2022; Accepted: Feb 23, 2022; Published: Feb 25, 2022


Uterine leiomyoma is a benign tumor that develops in the myometrium of the uterus. Estrogen is involved in the development and increase of uterine leiomyoma, and even in patients who had strong symptoms before menopause, uterine leiomyoma significantly shrinks after menopause. However, since the cells of uterine leiomyoma have a wide variety of properties, various pathological conditions of uterine leiomyoma are observed in clinical practice. Intravenous leiomyomatosis (IVL) is a relatively rare benign tumor in which smooth muscle tissue grows and spreads intravenously. Intravenous leiomyoma is histologically benign, but it is an important disease that sometimes spreads continuously to the inferior vena cava and the heart and can cause sudden death. Benign metastasizing leiomyoma (BML) is a condition in which metastatic lesions of benign leiomyoma are found in distant organs in women with a history of uterine leiomyoma. In BML, metastasis to the lung is most common. In this editorial, we discuss the several types of uterine leiomyoma with the latest information.


Leiomyoma; Intravenous leiomyomatosis; Benign metastasizing leiomyoma; Leiomyosarcoma.